Report Overview

The South Korea Pompe Disease size stood at around USD xx billion in 2019 and is projected to reach xx billion by 2028, exhibiting a CAGR of around 2.8% during the forecast period.

Pompe disease is a progressive neuromuscular disease that shows signs of irreversible muscle damage and respiratory depression due to accumulation of sugar source in muscle cells because of deficiency or lack of lysosomal enzymes. This build-up occurs in organs and tissues, especially in muscles, causing them to break down. The additional glycogen builds up in the patient and is stored in skeletal muscle, heart, and other tissues, which causes the progressive indications of Pompe disease.

It is known to occurs infrequently, with an average of 1 out of 40,000 people, and the incidence frequency is very different according to race.

Market Drivers

The increase in the prevalence of Pompe disease is driving the Pompe disease market owing towards the increase of manufacturers focusing on expanding their pipeline to cater to the demand for Pompe disease treatment. Government has taken initiatives for developing and manufacturing innovative products for the diagnosis & treatment of Pompe disease is the other major factor driving growth of the Pompe Disease market.

Factor restraining the growth of the market is lack of cost-effective treatment. Available treatment options are very expensive, and lack of FDA approved drugs leads to the less affordability rate.